Dr. George Carrum, MD
Claim this profileHouston Methodist Hospital
Studies Lymphoma
Studies Acute Lymphoblastic Leukemia
7 reported clinical trials
25 drugs studied
Area of expertise
1Lymphoma
HLA-A negative
HLA-A positive
HLA positive
2Acute Lymphoblastic Leukemia
HLA-A negative
HLA-A positive
HLA positive
Affiliated Hospitals
Clinical Trials George Carrum, MD is currently running
Stem Cell Transplantation
for Leukemia
This is a prospective, multi-center, Phase II study of hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-mismatched unrelated donors (MMUD) for peripheral blood stem cell transplant in adults and bone marrow stem cell transplant in children. Post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate mofetil (MMF) will be used for for graft versus host disease (GVHD) prophylaxis. This trial will study how well this treatment works in patients with hematologic malignancies.
Recruiting1 award Phase 2
HLA-matched VSTs
for Viral Infections Post Stem Cell Transplant
The purpose of this study is to use VSTs (virus-specific T cells) from a donor that is a partial HLA (human leukocyte antigen) match with the patient to treat viral infections after an allogeneic hematopoietic stem cell transplant (HSCT). These cells may also have value in CAR-T recipients who have received a product that depletes virus specific T cells. The patient must have had a myeloablative or non-myeloablative allogeneic HSCT using either bone marrow, single/double umbilical cord blood, or peripheral blood stem cells (PBSC) or CAR T cell product targeting an antigen expressed on virus specific T cells. After a transplant, while the immune system grows back, the patient is at risk for infection. Some viruses can stay in the body for life and are normally controlled by a healthy immune system, but if the immune system is weakened, like after a transplant, they can cause life threatening infections. He/she must have had an infection with one or more of the following viruses -Epstein Barr virus (EBV), cytomegalovirus (CMV), adenovirus (AdV), Human polyomavirus type I (BKV), and human polyomavirus type II (JCV)- that has persisted or recurred despite standard therapy. In this study, the investigators want to use white blood cells that have been trained to treat viral infections. In an earlier study the investigators showed that treatment with such specially trained T cells has been successful when the cells are made from the transplant donor. However as it takes 1-2 months to make the cells, that approach is not practical for patients who already have an infection. In a subsequent study, the investigators were able to create multivirus-specific T cells (VSTs) from the blood of healthy donors and created a bank of these cells. The investigators then successfully used these banked cells to treat virus infections after a stem cell transplant. In this study the investigators have further modified their production method to decrease the potential side effects and the investigators want to find out if they can use these banked VSTs to fight infections caused by the viruses mentioned above.
Recruiting1 award Phase 19 criteria
More about George Carrum, MD
Clinical Trial Related1 year of experience running clinical trials · Led 7 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments George Carrum, MD has experience with
- CTL019
- Allogeneic Hematopoietic Stem Cell Transplantation
- Best Practice
- Clinical Management
- Quality-of-Life Assessment
- Questionnaire Administration
Breakdown of trials George Carrum, MD has run
Lymphoma
Acute Lymphoblastic Leukemia
Lymphoid Leukemia
Leukemia
Myelodysplastic syndrome
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does George Carrum, MD specialize in?
George Carrum, MD focuses on Lymphoma and Acute Lymphoblastic Leukemia. In particular, much of their work with Lymphoma has involved HLA-A negative patients, or patients who are HLA-A positive.
Is George Carrum, MD currently recruiting for clinical trials?
Yes, George Carrum, MD is currently recruiting for 2 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that George Carrum, MD has studied deeply?
Yes, George Carrum, MD has studied treatments such as CTL019, Allogeneic Hematopoietic Stem Cell Transplantation, Best Practice.
What is the best way to schedule an appointment with George Carrum, MD?
Apply for one of the trials that George Carrum, MD is conducting.
What is the office address of George Carrum, MD?
The office of George Carrum, MD is located at: Houston Methodist Hospital, Houston, Texas 77003 United States. This is the address for their practice at the Houston Methodist Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.